title: [Management of pituitary adenoma in pregnancy].
abstract: OBJECTIVE
  To discuss the management of pituitary adenoma during gestation, labor and lactation.
  
  
  METHODS
  This is a clinical retrospective analysis. 41 cases of pituitary adenoma in pregnancy and their treatment before conception and outcomes of pregnancy were analyzed.
  
  
  RESULTS
  (1) The incidence of pituitary adenoma in pregnancy was 1.02%. (2) Women received bromocriptin only before pregnancy accounted for 85.77%. (3) Neurological symptoms occurred in 39.03% of the patients during gestation. (4) 30 patients (73.17%) kept on bromocriptin treatment during pregnancy, and no adverse effects on fetus were seen. (5) 75.00% of the patients were breastfeeding and no abnormal symptoms were shown.
  
  
  CONCLUSIONS
  Bromocriptin treatment during pregnancy was safe and effective for women with pituitary adenoma, and breastfeeding was not contraindicated.
authors.affiliation: Obsterics and Gynecology Hospital, Shanghai Medical University.
authors.forename: W
authors.initials: W
authors.lastname: Cheng
authors.forename: Z
authors.initials: Z
authors.lastname: Zhang
mesh_terms: D000236:Adenoma / Q000188:drug therapy*; D001942:Breast Feeding; D001971:Bromocriptine / Q000627:therapeutic use*; D002585:Cesarean Section; D018491:Dopamine Agonists / Q000627:therapeutic use*; D005260:Female; D006727:Hormone Antagonists / Q000627:therapeutic use*; D006801:Humans; D010911:Pituitary Neoplasms / Q000188:drug therapy*; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy*; D012189:Retrospective Studies
chemical_list: D018491:Dopamine Agonists; D006727:Hormone Antagonists; D001971:Bromocriptine